This company has been acquired
Myovant Sciences Balance Sheet Health
Financial Health criteria checks 1/6
Key information
-64.3%
Debt to equity ratio
US$358.70m
Debt
| Interest coverage ratio | n/a |
| Cash | US$274.44m |
| Equity | -US$558.14m |
| Total liabilities | US$961.66m |
| Total assets | US$403.52m |
Recent financial health updates
Recent updates
Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M
Jan 26Not The Buyout Offer That Myovant Shareholders Hoped For
Oct 25Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer
Oct 03Women Can Thank Pfizer And Myovant For MYFEMBREE
Sep 20Myovant Sciences: Regulatory Overhang Cleared
Aug 29Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication
Aug 09Myovant stock gains ~6% after hours on Q1 revenue jump
Jul 27Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree
Jul 18Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Apr 28
Myovant: Poised To Overcome Regulatory Issues
Apr 26Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels
Apr 13Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play
Mar 26Myovant: Catalysts Powering More Upside
Jan 02Myovant Sciences: Becoming A Blockbuster
Jun 02Myovant Sciences rises on FDA approval for relugolix
May 26Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates
May 14Why The Misunderstood Pfizer Deal Makes Myovant A Great Low-Risk Investment
May 09New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)
Feb 17Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates
Feb 13Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Jan 12Myovant cut to neutral at Goldman Sachs on ‘lack of driving catalysts’
Jan 06Myovant Sciences announces distribution of ORGOVYX in the U.S.
Jan 05Myovant Sciences gains 22% on relugolix deal with Pfizer
Dec 28Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?
Dec 23
Myovant Sciences’ FDA win leads to Bullish views at Baird
Dec 21Myovant Sciences scores FDA approval for Orgovyx in prostate cancer
Dec 18Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain
Nov 18Myovant Sciences: More Than Meets The Eye
Nov 12The Sell-Off In Myovant Is Unjustified By Fundamentals
Nov 09Financial Position Analysis
Short Term Liabilities: MYOV has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: MYOV has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: MYOV has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: MYOV's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MYOV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MYOV has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.3% each year.